MMAE

AcronymDefinition
MMAEMonomethyl Auristatin E
MMAEMechanical, Materials and Aerospace Engineering
MMAEMultiple Model Adaptive Estimation (Bayesian technique using Kalman filters)
MMAEMultiple Model Adaptive Estimator
MMAEMethod of Matched Asymptotic Expansions
MMAEMoses Montefiore Anshe Emunah (Baltimore, MD)
References in periodicals archive ?
The MMAE is a very good measure to break down different models to one number.
The method is easily applicable since it does not require any matching principle in contrast to the well-known method matched asymptotic expansions (MMAE).
Newman et al., "CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin," Molecular Cancer Therapeutics, vol.
Abbreviations ASCT: Autologous stem cell transplant CTA: Computed tomography angiogram MMAE: Monomethyl auristatin E.
Measurement of circulating specific cytotoxic ADCs are extremely important for pre-clinical and clinical studies Based on the specific antibodies against DM1, MMAE, MMAF, Epitope Diagnostics has developed three enzyme immunoassay (EIA) kits measuring DM1-ADC, MMAE-ADC, and MMAF-ADC (respective antibody conjugates).
The sharp end of the stick in DMUC5754A is a toxin called mono-methyl auristatin E, or MMAE, which must be wielded carefully.
Mean absolute error (MAE) was calculated by taking arithmetic mean of the absolute deviations between each observation and forecast and monthly mean absolute error (MMAE), describing seasonal variation of the forecast error, was found as the arithmetic mean of MAE over the one month period.
The monoclonal antibody delivers a highly potent molecule called monomethyl auristatin E (MMAE) to selectively kill the pancreatic cancer cells.
Seattle Genetics has developed a technology employing synthetic, highly potent cell-killing agents called auristatins (such as MMAE and MMAF) and stable linker systems that attach auristatin to the antibody.
SGN-35 is an ADC comprised of an anti-CD30 antibody joined by an enzyme cleavable linker to a synthetic drug payload, monomethyl auristatin E (MMAE), using Seattle Genetics' proprietary technology.
The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalisation into CD30-positive tumor cells.
Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) designed to target Tissue Factor antigen on cancer cell surfaces and deliver the cell-killing agent monomethyl auristatin E (MMAE) directly inside cancer cells.